What Happens To AbbVie Stock If SKYRIZI Slows Down

AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink. The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.

AbbVie's Growth Now Leans On Two Drugs

In the quarter ended June 2026, AbbVie took in nearly $17 billion of revenue. SKYRIZI, its treatment for psoriasis and Crohn's disease, was $5.5 billion of that, about a third of the whole company. It grew 24% on an operational basis. RINVOQ, its other big immunology drug, and the neuroscience business grew at a similar pace.

Other parts of the business went the other way. HUMIRA fell 36%, also on an operational basis, under biosimilar competition, and both oncology and aesthetics shrank. SKYRIZI, RINVOQ and the neuroscience business drive the company's growth now, and SKYRIZI is by far the largest of the growers, so what could slow SKYRIZI is the question that matters.

But SKYRIZI Already Has A New Rival

The first threat is on the market: a new oral psoriasis drug launched in March. Management says it has not dented SKYRIZI so far: the newcomer draws most of its patients from the two other oral treatments, and SKYRIZI's new and switching patient starts have grown since the launch. That is the company's own tracking, and it covers only a few months.

The second threat comes every year, when payers negotiate price. Management calls immunology a volume business in which payers take low-single-digit concessions on price and rebates, and says the latest round has so far run like past ones.

The third threat carries dates. SKYRIZI's composition of matter patent runs to 2033 and its regulatory data protection to 2031, though the company says later patents, granted and pending, run into the mid-2030s and later. The company is already buying for the years after that: its acquisition of Apogee Therapeutics adds immunology assets the CEO calls a source of growth for the 2030s and beyond.

And What Would A Stumble Cost You?

More than the lost sales would explain, because the price already assumes the engine keeps running. Inside the past year's run, the stock's largest fall was about 17% from peak to trough. The options market is not calm: implied volatility sits in the 73rd percentile of its one-year range, a larger expected move than usual.

A slowdown in SKYRIZI would not arrive as an event. It would show up as a growth rate a few points lower than the quarter before, while the older drugs keep shrinking. The risk is real, and it is slow.

Two checks are dated. The FDA is due to rule in the fall of 2026 on a subcutaneous induction dose of SKYRIZI for Crohn's disease, which management expects to lift growth from early 2027. AbbVie's report for the quarter ending September 2026 will show whether SKYRIZI is still growing above 20%. Until those catalysts lands, check how large a move the options market is pricing; this close to a 52-week high, the swing runs both ways.

Would A Threat Like This Reach Your Retirement?

A threat like the one above is a footnote for a diversified holder and a headline for a concentrated one. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.